Oncology and Autoimmune Diseases
(1) Rheumatoid arthritis involves a complicated pathogenesis. B1451 can reduce inflammatory reactions through multiple channels and multiple mechanisms, including inhibiting angiogenesis, down-regulating inflammatory factors, and inhibiting chemotaxis of inflammatory cells, thereby enhancing drug effectiveness and avoiding the development of drug resistance to or ineffective treatment from monotherapy;
(2) B1451 uses long-acting protein drug development technology, significantly prolongs the half-life of HM-3, and is administered at a frequency of 1 to 2 weeks, which helps improve the patient’s treatment compliance;
(3) A protein yield of up to 35 g/L, along with a high cost-effectiveness ratio;
Next important events and time points
It is anticipated that preclinical pharmacodynamics, pharmacokinetics and safety evaluation studies will be initiated in the third quarter of 2022, and an IND application will be filed in the last quarter of 2023.